̽»¨¾«Ñ¡

Cecilia Radkiewicz

Cecilia Radkiewicz

Affiliated to Research
Visiting address: Nobels väg 12a, 17165 Solna
Postal address: C8 Medicinsk epidemiologi och biostatistik, C8 MEB Dickman, 171 77 Stockholm

About me

  • Postdoctoral researcher in cancer epidemiology, Jesper Lagergren's group
    Assistant consultant in ̽»¨¾«Ñ¡ oncology, Capio Sankt Görans Sjukhus
    Director of studies, the Research School in Epidemiology for Clinicians 


  • 2020/2022

    I have a combined employment, performing cancer epidemiology research together with clinical work as a ̽»¨¾«Ñ¡ oncologist at the Department of Molecular Medicine, ̽»¨¾«Ñ¡ and Capio Sankt Görans Sjukhus, respectively.

    PhD, medicine, ̽»¨¾«Ñ¡, 2019
    Specialist degree, ̽»¨¾«Ñ¡ oncology, Swedish National Board of Health and
    Welfare, 2018
    MD, Swedish National Board of Health and Welfare, 2010
    BSc, medicine, ̽»¨¾«Ñ¡, 2008

Research

  • The primary focus of my research is in clinical cancer epidemiology. I handle big volumes of data by linking multiple Swedish and Nordic population-based health and demographic registers with high national coverage. This enables robust analyses of trends over different time axis. I use state-of-the-art statistical methods to describe and illustrate observational research findings to enable clinical inferences. When quantifying cancer mortality and contrasting survival between patient populations, I apply relative survival and flexible parametric regression models, respectively. I am particularly interested in applying interactive, pedagogic tools to present research findings.

     

  • Swedish Anti-Cancer Therapy (SeACT)

    I am the primary investigator and driving force behind the SeACT project, an academic initiative aiming to collect Swedish ̽»¨¾«Ñ¡ record data on cancer drugs from the electronic prescription systems CytoBase, Cytodos, and Mosaiq in order to conduct pharmacoepidemiological studies on cancer treatment in Sweden. The study has been ethically reviewed, with ̽»¨¾«Ñ¡ as the main institution.


    Background: Around 70, 000 individuals are diagnosed with malignancy in Sweden each year. Incidence is increasing, while a larger proportion of cancer patients are being cured or live longer with cancer. Early detection and treatment, as well as new medications and optimized treatment algorithms, have contributed to this. In routine healthcare, the impact on mortality is however lower, and the risk of side effects higher compared to clinical trials on selected patient groups with short follow-up. Despite serious side effects and high drug costs, it is today not possible to systematically monitor the effectiveness and safety of cancer drugs in Sweden.

     

  • Main Objective: To perform phase IV (real-world data) studies on the short- and long-term effects and safety, as well as access to cancer drugs in a Swedish population-based setting.

     

  • Study Design and Data Collection: Most cancer drugs are administered as requisition drugs in hospitals. Since around 20 years back, this information is stored in a handful of electronic prescription systems (Cytodos, CytoBase, and Mosaiq) in Sweden. We plan to link treatment data from these prescription systems and the National Prescribed Drug Register to all individuals in the National Cancer Register. Subsequently the cancer cohort will be linked to other population-based health and demographic registers including the National Cause of Death, Patient, Medical Births Registers (the National Board of Health and Welfare) and the and Total Population Register and LISA database (Statistics Sweden), respecively.


    The statistical analysis will be carried out as a series of retrospective cohort studies where we (depending on the specific research question) will follow Swedish cancer patients from date of diagnosis, relapse, surgery, or treatment start. The focus is real-world cancer survival and to assess acute and late side effects, between different treatments and patient groups. We will also study how these outcomes are affected by age, sex, comorbidity, and other medications.


    Timeline: As of 2024, requests are being submitted to all Swedish healthcare regions/providers to obtain anti-cancer therapy data from their respective electronic prescription system. We hope to have collected treatment data from all regions by mid-2025, and the first sub-study is expected to be submitted for publication in 2026.

Teaching

  • Throughout my oncology residency I have been committed to teaching and leading seminars in clinical oncology as a part of the ̽»¨¾«Ñ¡ education at
    ̽»¨¾«Ñ¡. In 2017/2018 I held a teaching position to coordinate and plan the education in palliative care for ̽»¨¾«Ñ¡ students as a part of the course in clinical oncology. I was responsible for the oncology rotation at the upper gastrointestinal department at Karolinska Universitetssjukhuset, Huddinge 2019-2022. In 2020-2022 I acted as director of studies at the KI/SLL Research School in Epidemiology for Clinicians, generation 19. Since 2024 I am responsible for arranging the Swedish Oncology Association run and recommended course in ̽»¨¾«Ñ¡ evdience for residents in oncology.

Articles

  • Article: EUROPEAN JOURNAL OF CANCER. 2025;214:115140
    Radkiewicz C; Ludvigsson JF; Sparrelid E; Emilsson L
  • Article: GASTROENTEROLOGY. 2024;167(3):485-492.e3
    Wiklund A-K; Santoni G; Yan J; Radkiewicz C; Xie S; Birgisson H; Ness-Jensen E; von Euler-Chelpin M; Kauppila JH; Lagergren J
  • Article: CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION. 2023;32(7):OF1-OF8
    Radkiewicz C; Asplund J; Lagergren J
  • Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2023;58(5):453-459
    Pettersson A-K; Santoni G; Yan J; Radkiewicz C; Xie S; Birgisson H; Ness-Jensen E; von Euler-Chelpin M; Kauppila JH; Lagergren J
  • Article: JNCI CANCER SPECTRUM. 2023;7(3):pkad038
    Radkiewicz C; Andersson TM-L; Lagergren J
  • Article: JOURNAL OF MEDICAL CASE REPORTS. 2023;17(1):132
    Akerstrom JH; Radkiewicz C
  • Article: ACTA ONCOLOGICA. 2023;62(2):103-109
    Wiken I; Andersson TM-L; Radkiewicz C
  • Article: AMERICAN JOURNAL OF HEMATOLOGY. 2023;98(1):23-30
    Radkiewicz C; Bruchfeld JB; Weibull CE; Jeppesen ML; Frederiksen H; Lambe M; Jakobsen L; El-Galaly TC; Smedby KE; Wasterlid T
  • Article: PANCREATOLOGY. 2023;23(1):90-97
    Holmberg M; Radkiewicz C; Stromberg C; Oman M; Ghorbani P; Lohr J-M; Sparrelid E
  • Article: EUROPEAN JOURNAL OF CANCER. 2022;175:291-298
    Rahman R; Ludvigsson JF; von Seth E; Lagergren J; Bergquist A; Radkiewicz C
  • Journal article: GASTROENTEROLOGY. 2022;162(7):s-501
    Emilsson L; Radkiewicz C; Semrad CE; Joshi AD; Ludvigsson JF
  • Article: CANCERS. 2022;14(3):469
    Emilsson L; Radkiewicz C; Semrad CE; Joshi AD; Ludvigsson JF
  • Article: CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION. 2022;31(1):280-286
    Radkiewicz C; Kronmark JJ; Adami H-O; Edgren G
  • Article: BLADDER CANCER. 2021;8(1):71-80
    Holmsten K; Omland LH; Als AB; Agerbaek M; Dohn LH; Lindberg H; Jensen NV; Carus A; Moe M; Hosseini A; Radkiewicz C; Pappot H; Ullen A
  • Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(15_suppl):e13593
    Radkiewicz C; Sjölander A; Benyi E; Lambe M; Dickman P; Sävendahl L; Edgren G
  • Article: CLINICAL GENITOURINARY CANCER. 2020;18(1):26-34.e6
    Radkiewicz C; Edgren G; Johansson ALV; Jahnson S; Haggstrom C; Akre O; Lambe M; Dickman PW
  • Article: PLOS ONE. 2019;14(6):e0219206
    Radkiewicz C; Dickman PW; Johansson ALV; Wagenius G; Edgren G; Lambe M
  • Article: EUROPEAN JOURNAL OF CANCER. 2017;84:130-140
    Radkiewicz C; Johansson ALV; Dickman PW; Lambe M; Edgren G

All other publications

  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2024
    Radkiewicz C; Asplund J; Lagergren J
  • Conference publication: ANNALS OF ONCOLOGY. 2023;34:s948
    Radkiewicz C; Andersson TM-L; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Radkiewicz C; Asplund J; Lagergren J
  • Letter: CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION. 2022;31(7):1506
    Radkiewicz C; Kronmark JJ; Adami H-O; Edgren G
  • Conference publication: GASTROENTEROLOGY. 2022;162(7):S501
    Emilsson L; Radkiewicz C; Semrad CE; Joshi AD; Ludvigsson JF
  • Meeting abstract: BLOOD. 2021;138:2534
    Radkiewicz C; Bruchfeld JB; Weibull C; Lambe M; Jakobsen LH; El-Galaly TC; Smedby KE; Wästerlid T
  • Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(15)
    Radkiewicz C; Sjolander A; Benyi E; Lambe M; Dickman P; Savendahl L; Edgren G
  • Thesis / dissertation: 2019
    Radkiewicz, Cecilia
  • Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2017;35:e13074
    Radkiewicz C; Johansson A; Dickman P; Lambe M; Edgren G
  • Show more

Employments

  • Affiliated to Research, Department of Medical Epidemiology and Biostatistics, ̽»¨¾«Ñ¡, 2024-2027
  • Affiliated to Research, Department of Molecular Medicine and Surgery, ̽»¨¾«Ñ¡, 2024-2025

Degrees and Education

  • Degree Of Doctor Of Philosophy, Department of Medical Epidemiology and Biostatistics, ̽»¨¾«Ñ¡, 2019
  • University Medical Degree, ̽»¨¾«Ñ¡, 2008

Supervisor

  • Anna-Klara Wiklund, The Nordic Helicobacter Pylori Eradication Project: Cancer risk after Helicobacter pylori therapy, 2021
  • Johanna Borg Bruchfeld, Sex-related differences in incidence and outcomes among patients with lymphoma: epidemiological and biological perspectives, /en/people/johanna-borg-bruchfeld, 2021

News from KI

Events from KI